Showing results (1661-1670 of 1,727) with videos related to

Sort By:
Pageof 173
BMC Medical Genetics|August 31, 2017
Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score methodGuo-Bo Chen, Sang Hong Lee, Grant W Montgomery, et al.
Scientific Reports|November 20, 2020
Ex vivo 18F-fluoride uptake and hydroxyapatite deposition in human coronary atherosclerosisAlastair J Moss, Alisia M Sim, Philip D Adamson, et al.
BMJ Open|July 2, 2021
Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocolBonita Gu, Michael De Gregorio, Joseph Louis Pipicella, et al.
Veterinary Immunology and Immunopathology|October 30, 2021
Horses affected by EPM have increased sCD14 compared to healthy horsesAlayna N Hay, Bettina Wagner, Caroline M Leeth, et al.
Nature|February 19, 2010
Signatures of mutation and selection in the cancer genomeGraham R Bignell, Chris D Greenman, Helen Davies, et al.
Iscience|March 3, 2023
Adaptation to compound climate risks: A systematic global stocktakeNicholas P Simpson, Portia Adade Williams, Katharine J Mach, et al.
Blood|February 9, 2026
Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy ResistanceHannah K Dorando, Jared M Andrews, Oam U Khatavkar, et al.
Alimentary Pharmacology & Therapeutics|May 27, 2016
Review article: acute severe ulcerative colitis - evidence-based consensus statementsJ-H Chen, J M Andrews, V Kariyawasam, et al.
Lancet (London, England)|July 20, 2025
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, Brian G Feagan, Anita Afzali, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2020
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposureEmma Flanagan, Peter R Gibson, Emily K Wright, et al.
Pageof 173